***Pharmaceutical Benefits Advisory Committee***

Email: PBAC@health.gov.au Address all mail to:

PBAC Secretariat

GPO Box 9848

Canberra ACT 2601

**DELISTING OF PHARMACEUTICAL BENEFIT ITEMS**

**EFFECTIVE 01 MAY 2025**

Following is the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act* *1953*, with effect from the above date.

|  |  |
| --- | --- |
| **Item** | **PBAC Advice** |
| Adefovir | The sponsor requested the delisting of APO-Adefovir (adefovir) from the Pharmaceutical Benefits Scheme (PBS).  The PBAC noted the low number of services in the last financial year and that there are alternatives on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need. |
| Cefotaxime | The sponsor requested the delisting of DBL Cefotaxime (cefotaxime) from PBS.  The PBAC noted the low number of services in the last financial year. The PBAC noted concerns about the delisting of antibiotics from the PBS and the impacts this can have for clinical choice and antimicrobial resistance. The PBAC advised the delisting of this product may result in an unmet clinical need and requested that the Department seek to retain this product. |
| Gentamicin | The sponsor requested the delisting of Pfizer Australia Pty Ltd (gentamicin) from the PBS.  The PBAC noted the moderate number of services in the last financial year and that there is a lack of appropriate alternatives on the PBS. The PBAC advised the delisting of this product may result in an unmet clinical and requested that the Department seek to retain this product. |
| Praziquantel | The sponsor requested the delisting of Biltricide® (praziquantel) from the PBS.  The PBAC noted the low number of services in the last financial year and that there are no suitable alternatives on the PBS. The PBAC advised the delisting of this product may result in an unmet clinical need and requested that the Department seek to retain this product. |

Andrew Case

Director (A/g), PBAC Governance

Office of Health Technology Assessment

Technology Assessment and Access Division

22 April 2025